-
1
-
-
0026081302
-
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase
-
Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zurcher G, Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991;11:2057-65.
-
(1991)
Mol Cell Biol
, vol.11
, pp. 2057-2065
-
-
Wilks, A.F.1
Harpur, A.G.2
Kurban, R.R.3
Ralph, S.J.4
Zurcher, G.5
Ziemiecki, A.6
-
2
-
-
0028268381
-
Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases
-
Takahashi T, Shirasawa T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett 1994;342:124-8.
-
(1994)
FEBS Lett
, vol.342
, pp. 124-128
-
-
Takahashi, T.1
Shirasawa, T.2
-
3
-
-
0025278593
-
Identification and chromosomal mapping of new human tyrosine kinase genes
-
Krolewski JJ, Lee R, Eddy R, Shows TB, Dalla-Favera R. Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene 1990;5:277-82.
-
(1990)
Oncogene
, vol.5
, pp. 277-282
-
-
Krolewski, J.J.1
Lee, R.2
Eddy, R.3
Shows, T.B.4
Dalla-Favera, R.5
-
4
-
-
80052492285
-
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
-
Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011;18:971-6.
-
(2011)
Nat Struct Mol Biol
, vol.18
, pp. 971-976
-
-
Ungureanu, D.1
Wu, J.2
Pekkala, T.3
Niranjan, Y.4
Young, C.5
Jensen, O.N.6
-
5
-
-
0034012330
-
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain
-
Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20:3387-95.
-
(2000)
Mol Cell Biol
, vol.20
, pp. 3387-3395
-
-
Saharinen, P.1
Takaluoma, K.2
Silvennoinen, O.3
-
6
-
-
0028835347
-
Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alphabbeta and for signal transduction
-
Velazquez L, Mogensen KE, Barbieri G, Fellous M, Uzé G, Pellegrini S. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alphabbeta and for signal transduction. J Biol Chem 1995;270:3327-34.
-
(1995)
J Biol Chem
, vol.270
, pp. 3327-3334
-
-
Velazquez, L.1
Mogensen, K.E.2
Barbieri, G.3
Fellous, M.4
Uzé, G.5
Pellegrini, S.6
-
7
-
-
0038371050
-
Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain
-
Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003;14:1448-59.
-
(2003)
Mol Biol Cell
, vol.14
, pp. 1448-1459
-
-
Saharinen, P.1
Vihinen, M.2
Silvennoinen, O.3
-
8
-
-
0030953469
-
Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop
-
Feng J, Witthuhn B, Matsuda T, Kohlhuber F, Kerr I, Ihle J. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 1997;17:2497-501.
-
(1997)
Mol Cell Biol
, vol.17
, pp. 2497-2501
-
-
Feng, J.1
Witthuhn, B.2
Matsuda, T.3
Kohlhuber, F.4
Kerr, I.5
Ihle, J.6
-
9
-
-
14744299761
-
Turning cells red: Signal transduction mediated by erythropoietin
-
Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15:146-55.
-
(2005)
Trends Cell Biol
, vol.15
, pp. 146-155
-
-
Richmond, T.D.1
Chohan, M.2
Barber, D.L.3
-
10
-
-
27144452311
-
JAK protein kinase inhibitors
-
Thompson JE. JAK protein kinase inhibitors. Drug News Perspect 2005;18:305-10.
-
(2005)
Drug News Perspect
, vol.18
, pp. 305-310
-
-
Thompson, J.E.1
-
11
-
-
32144453842
-
JAK1STAT signal transduction: Regulators and implication in hematological malignancies
-
Valentino L, Pierre J. JAK1STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006;71:713-21.
-
(2006)
Biochem Pharmacol
, vol.71
, pp. 713-721
-
-
Valentino, L.1
Pierre, J.2
-
12
-
-
17844383458
-
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
-
James C, Ugo V, Le Couedic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
-
(2005)
Nature
, vol.434
, pp. 1144-1148
-
-
James, C.1
Ugo, V.2
Le Couedic, J.-P.3
Staerk, J.4
Delhommeau, F.5
Lacout, C.6
-
13
-
-
20244369569
-
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
-
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
-
(2005)
Cancer Cell
, vol.7
, pp. 387-397
-
-
Levine, R.L.1
Wadleigh, M.2
Cools, J.3
Ebert, B.L.4
Wernig, G.5
Huntly, B.J.P.6
-
14
-
-
57749188299
-
Targeting cancer with small molecule kinase inhibitors
-
Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 28-39
-
-
Zhang, J.1
Yang, P.L.2
Gray, N.S.3
-
15
-
-
13344295097
-
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
-
Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379:645-8.
-
(1996)
Nature
, vol.379
, pp. 645-648
-
-
Meydan, N.1
Grunberger, T.2
Dadi, H.3
Shahar, M.4
Arpaia, E.5
Lapidot, Z.6
-
16
-
-
0028223221
-
Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program
-
Posner I, Engel M, Gazit A, Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol 1994;45:673-83.
-
(1994)
Mol Pharmacol
, vol.45
, pp. 673-683
-
-
Posner, I.1
Engel, M.2
Gazit, A.3
Levitzki, A.4
-
17
-
-
0037156334
-
Photochemical preparation of a pyridone containing tetracycle: A jak protein kinase inhibitor
-
Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, et al. Photochemical preparation of a pyridone containing tetracycle: A jak protein kinase inhibitor. Bioorg Med Chem Lett 2002;12:1219-23.
-
(2002)
Bioorg Med Chem Lett
, vol.12
, pp. 1219-1223
-
-
Thompson, J.E.1
Cubbon, R.M.2
Cummings, R.T.3
Wicker, L.S.4
Frankshun, R.5
Cunningham, B.R.6
-
18
-
-
0242332186
-
Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor
-
Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor. Science 2003;302:875-8.
-
(2003)
Science
, vol.302
, pp. 875-878
-
-
Changelian, P.S.1
Flanagan, M.E.2
Ball, D.J.3
Kent, C.R.4
Magnuson, K.S.5
Martin, W.H.6
-
20
-
-
33749239636
-
Gö6976 is a potent inhibitor of the JAK2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells
-
Grandage VL, Everington T, Linch DC, Khwaja A. Gö6976 is a potent inhibitor of the JAK2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006;135:303-16.
-
(2006)
Br J Haematol
, vol.135
, pp. 303-316
-
-
Grandage, V.L.1
Everington, T.2
Linch, D.C.3
Khwaja, A.4
-
21
-
-
69449087032
-
SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling
-
Haan S, Wuller S, Kaczor J, Rolvering C, Nocker T, Behrmann I, et al. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene 2009;28:3069-80.
-
(2009)
Oncogene
, vol.28
, pp. 3069-3080
-
-
Haan, S.1
Wuller, S.2
Kaczor, J.3
Rolvering, C.4
Nocker, T.5
Behrmann, I.6
-
22
-
-
80755140046
-
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
-
Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011;25:1751-9.
-
(2011)
Leukemia
, vol.25
, pp. 1751-1759
-
-
Hart, S.1
Goh, K.C.2
Novotny-Diermayr, V.3
Hu, C.Y.4
Hentze, H.5
Tan, Y.C.6
-
23
-
-
33644546402
-
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders
-
Quentmeier H, MacLeod RAF, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006;20:471-6.
-
(2006)
Leukemia
, vol.20
, pp. 471-476
-
-
Quentmeier, H.1
McLeod, R.A.F.2
Zaborski, M.3
Drexler, H.G.4
-
24
-
-
77954619670
-
Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805
-
Baffert F, Régnier CH, De Pover A, Pissot-Soldermann C, Tavares GA, Blasco F, et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther 2010;9:1945-55.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 1945-1955
-
-
Baffert, F.1
Régnier, C.H.2
de Pover, A.3
Pissot-Soldermann, C.4
Tavares, G.A.5
Blasco, F.6
-
25
-
-
33746437130
-
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
-
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
-
(2006)
PLoS Med
, vol.3
-
-
Pikman, Y.1
Lee, B.H.2
Mercher, T.3
McDowell, E.4
Ebert, B.L.5
Gozo, M.6
-
26
-
-
70350519430
-
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
-
Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009;114:2688-98.
-
(2009)
Blood
, vol.114
, pp. 2688-2698
-
-
Russell, L.J.1
Capasso, M.2
Vater, I.3
Akasaka, T.4
Bernard, O.A.5
Calasanz, M.J.6
-
27
-
-
15444339209
-
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
-
Lacronique V, Boureux A, Della Valle V, Poirel H, Quang CT, Mauchauffe M, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309-12.
-
(1997)
Science
, vol.278
, pp. 1309-1312
-
-
Lacronique, V.1
Boureux, A.2
della Valle, V.3
Poirel, H.4
Quang, C.T.5
Mauchauffe, M.6
-
28
-
-
70349232895
-
Selective reduction of JAK2V617F-dependent cell growth by siRNAa shRNA and its reversal by cytokines
-
Jedidi A, Marty C, Oligo C, Jeanson-Leh L, Ribeil J-A, Casadevall N, et al. Selective reduction of JAK2V617F-dependent cell growth by siRNAa shRNA and its reversal by cytokines. Blood 2009;114:1842-51.
-
(2009)
Blood
, vol.114
, pp. 1842-1851
-
-
Jedidi, A.1
Marty, C.2
Oligo, C.3
Jeanson-Leh, L.4
Ribeil, J-A.5
Casadevall, N.6
-
29
-
-
33745713168
-
Activating alleles of JAK3 in acute megakaryoblastic leukemia
-
Walters DK, Mercher T, Gu T-L, O'Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
-
(2006)
Cancer Cell
, vol.10
, pp. 65-75
-
-
Walters, D.K.1
Mercher, T.2
Gu, T-L.3
O'Hare, T.4
Tyner, J.W.5
Loriaux, M.6
-
30
-
-
79953043687
-
Jak1 has a dominant role over Jak3 in signal transduction through c-containing cytokine receptors
-
Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thoma G, et al. Jak1 has a dominant role over Jak3 in signal transduction through c-containing cytokine receptors. Chem Biol 2011;18:314-23.
-
(2011)
Chem Biol
, vol.18
, pp. 314-323
-
-
Haan, C.1
Rolvering, C.2
Raulf, F.3
Kapp, M.4
Drückes, P.5
Thoma, G.6
-
31
-
-
29644439240
-
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation
-
Staerk J, Kallin A, Demoulin J-B, Vainchenker W, Constantinescu SN. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation. J Biol Chem 2005;280:41893-9.
-
(2005)
J Biol Chem
, vol.280
, pp. 41893-41899
-
-
Staerk, J.1
Kallin, A.2
Demoulin, J-B.3
Vainchenker, W.4
Constantinescu, S.N.5
-
32
-
-
77953872197
-
Rational design of T315I BCR-Abl inhibitors for the treatment of drug-resistant chronic myelogenous leukemia (CML): BGG463
-
Manley PW, Brüggen J, Floersheimer A, Furet P, Jensen MR, Mestan J, et al. Rational design of T315I BCR-Abl inhibitors for the treatment of drug-resistant chronic myelogenous leukemia (CML): BGG463. Chimia 2008;62:579.
-
(2008)
Chimia
, vol.62
, pp. 579
-
-
Manley, P.W.1
Brüggen, J.2
Floersheimer, A.3
Furet, P.4
Jensen, M.R.5
Mestan, J.6
-
33
-
-
30144436273
-
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
-
Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006;107:176-83.
-
(2006)
Blood
, vol.107
, pp. 176-183
-
-
Lucet, I.S.1
Fantino, E.2
Styles, M.3
Bamert, R.4
Patel, O.5
Broughton, S.E.6
-
34
-
-
2442637820
-
Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity
-
Argetsinger LS, Kouadio J-LK, Steen H, Stensballe A, Jensen ON, Carter-Su C. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol 2004;24:4955-67.
-
(2004)
Mol Cell Biol
, vol.24
, pp. 4955-4967
-
-
Argetsinger, L.S.1
Kouadio, J-L.K.2
Steen, H.3
Stensballe, A.4
Jensen, O.N.5
Carter-Su, C.6
-
35
-
-
34548351250
-
Modulation of protein tyrosine phosphatase 1B by erythropoietin in UT-7 cell line
-
Callero M, Pérez G, Vittori D, Pregi N, Nesse A. Modulation of protein tyrosine phosphatase 1B by erythropoietin in UT-7 cell line. Cell Physiol Biochem 2007;20:319-28.
-
(2007)
Cell Physiol Biochem
, vol.20
, pp. 319-328
-
-
Callero, M.1
Pérez, G.2
Vittori, D.3
Pregi, N.4
Nesse, A.5
-
36
-
-
20244389693
-
The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop
-
Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999;18:1309-20.
-
(1999)
EMBO J
, vol.18
, pp. 1309-1320
-
-
Yasukawa, H.1
Misawa, H.2
Sakamoto, H.3
Masuhara, M.4
Sasaki, A.5
Wakioka, T.6
-
37
-
-
23044495944
-
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog
-
Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 2005;106:996-1002.
-
(2005)
Blood
, vol.106
, pp. 996-1002
-
-
Boggon, T.J.1
Li, Y.2
Manley, P.W.3
Eck, M.J.4
-
38
-
-
0033522422
-
Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling
-
Takaoka A, Tanaka N, Mitani Y, Miyazaki T, Fujii H, Sato M, et al. Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling. EMBO J 1999;18:2480-8.
-
(1999)
EMBO J
, vol.18
, pp. 2480-2488
-
-
Takaoka, A.1
Tanaka, N.2
Mitani, Y.3
Miyazaki, T.4
Fujii, H.5
Sato, M.6
-
39
-
-
18244393495
-
Unexpected effects of FERM domain mutations on catalytic activity of Jak3: Structural implication for janus kinases
-
Zhou Y-J, Chen M, Cusack NA, Kimmel LH, Magnuson KS, Boyd JG, et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for janus kinases. Mol Cell 2001;8:959-69.
-
(2001)
Mol Cell
, vol.8
, pp. 959-969
-
-
Zhou, Y-J.1
Chen, M.2
Cusack, N.A.3
Kimmel, L.H.4
Magnuson, K.S.5
Boyd, J.G.6
-
40
-
-
77955299093
-
JAK2 V617F constitutive activation requires JH2 residue F595: A pseudokinase domain target for specific inhibitors
-
Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One 2010;5:e11157.
-
(2010)
PLoS One
, vol.5
-
-
Dusa, A.1
Mouton, C.2
Pecquet, C.3
Herman, M.4
Constantinescu, S.N.5
-
41
-
-
43549109620
-
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
-
Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008;111:3751-9.
-
(2008)
Blood
, vol.111
, pp. 3751-3759
-
-
Wernig, G.1
Gonneville, J.R.2
Crowley, B.J.3
Rodrigues, M.S.4
Reddy, M.M.5
Hudon, H.E.6
-
42
-
-
63149194964
-
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
-
Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, et al. V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009;106:4519-24.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 4519-4524
-
-
Pratilas, C.A.1
Taylor, B.S.2
Ye, Q.3
Viale, A.4
Sander, C.5
Solit, D.B.6
-
43
-
-
34547933680
-
Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition
-
Han EKH, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 2007;26:5655-61.
-
(2007)
Oncogene
, vol.26
, pp. 5655-5661
-
-
Han, E.K.H.1
Leverson, J.D.2
McGonigal, T.3
Shah, O.J.4
Woods, K.W.5
Hunter, T.6
-
44
-
-
77949685981
-
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
-
Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
-
(2010)
Nature
, vol.464
, pp. 431-435
-
-
Hatzivassiliou, G.1
Song, K.2
Yen, I.3
Brandhuber, B.J.4
Anderson, D.J.5
Alvarado, R.6
-
45
-
-
0033965488
-
Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains
-
Chen M, Cheng A, Candotti F, Zhou Y-J, Hymel A, Fasth A, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 2000;20:947-56.
-
(2000)
Mol Cell Biol
, vol.20
, pp. 947-956
-
-
Chen, M.1
Cheng, A.2
Candotti, F.3
Zhou, Y-J.4
Hymel, A.5
Fasth, A.6
-
46
-
-
0030729823
-
Structural and functional basis for JAK3-deficient severe combined immunodeficiency
-
Candotti F, Oakes SA, Johnston JA, Giliani S, Schumacher RF, Mella P, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 1997;90:3996-4003.
-
(1997)
Blood
, vol.90
, pp. 3996-4003
-
-
Candotti, F.1
Oakes, S.A.2
Johnston, J.A.3
Giliani, S.4
Schumacher, R.F.5
Mella, P.6
-
47
-
-
54349086521
-
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
-
Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484-92.
-
(2008)
Lancet
, vol.372
, pp. 1484-1492
-
-
Bercovich, D.1
Ganmore, I.2
Scott, L.M.3
Wainreb, G.4
Birger, Y.5
Elimelech, A.6
-
48
-
-
41949128173
-
CASK functions as a Mg2+-independent neurexin kinase
-
Mukherjee K, Sharma M, Urlaub H, Bourenkov GP, Jahn R, Südhof TC, et al. CASK functions as a Mg2+-independent neurexin kinase. Cell 2008;133:328-39.
-
(2008)
Cell
, vol.133
, pp. 328-339
-
-
Mukherjee, K.1
Sharma, M.2
Urlaub, H.3
Bourenkov, G.P.4
Jahn, R.5
Südhof, T.C.6
-
49
-
-
77952338791
-
ErbB34 HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
-
Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB34 HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A 2010;107:7692-7.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 7692-7697
-
-
Shi, F.1
Telesco, S.E.2
Liu, Y.3
Radhakrishnan, R.4
Lemmon, M.A.5
-
50
-
-
77950037732
-
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors
-
Pissot-Soldermann C, Gerspacher M, Furet P, Gaul C, Holzer P, McCarthy C, et al. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Bioorg Med Chem Lett 2010;20:2609-13.
-
(2010)
Bioorg Med Chem Lett
, vol.20
, pp. 2609-2613
-
-
Pissot-Soldermann, C.1
Gerspacher, M.2
Furet, P.3
Gaul, C.4
Holzer, P.5
McCarthy, C.6
|